What the Medicare Part D Drug Cap Means at the Pharmacy

Two Changes That Took Effect in January

Two significant changes to Medicare prescription drug coverage went into effect on January 1, 2026, and they are working together to reduce costs for some of the highest-need enrollees in the program. The first is an annual cap on out-of-pocket prescription drug spending. The second is the debut of lower negotiated prices on ten high-cost medications. Understanding how both work - and who benefits - requires a look at the structure of Medicare Part D.

The 2,100-dollar cap and the drug price negotiations both stem from the Inflation Reduction Act of 2022. They represent the most significant structural changes to Medicare Part D in the program’s history.

How the Out-of-Pocket Cap Works

In 2024, Medicare Part D enrollees had to spend 8,000 dollars out of pocket on covered medications before entering catastrophic coverage - the phase where a plan pays 100 percent of costs for the rest of the year. That threshold dropped to 2,000 dollars in 2025 and has been adjusted to 2,100 dollars in 2026, with annual inflation-based adjustments going forward.

According to GoodRx, once an enrollee’s cumulative out-of-pocket spending on covered Part D drugs reaches 2,100 dollars in 2026, their plan pays the full cost of covered medications for the remainder of the calendar year. The cap applies automatically - no additional enrollment is required - and it applies to standalone Part D plans and Medicare Advantage plans that include prescription drug coverage.

The donut hole coverage gap, which previously created unpredictable spikes in drug costs for many enrollees, was permanently eliminated at the end of 2024. The 2026 benefit structure now runs from a deductible phase directly to an initial coverage phase, then into catastrophic coverage once the 2,100-dollar threshold is reached.

The 10 Negotiated Drugs

For the first time in Medicare’s history, the program has directly negotiated prices with pharmaceutical manufacturers. Ten Part D drugs - selected based on their high cost and widespread use - now carry what CMS calls Maximum Fair Prices, which took effect January 1, 2026.

According to AARP, the drugs cover a range of conditions including heart disease, diabetes, autoimmune disorders, and cancer. The list includes Eliquis, Jardiance, and Xarelto, among others. AARP’s analysis of stand-alone Part D plans found that average out-of-pocket costs for the 56 plans reviewed would be less than 100 dollars per month for seven of the ten negotiated drugs - compared to only two of the ten in 2025. Out-of-pocket costs for the ten drugs are projected to fall by an average of more than 50 percent for eligible beneficiaries enrolled in original Medicare.

CMS estimates that approximately 9 million Medicare Part D enrollees use one or more of the ten negotiated drugs and could see savings. Total projected savings across all Part D enrollees in 2026 from the negotiated prices alone amount to 1.5 billion dollars.

Who Benefits Most

The combination of the 2,100-dollar cap and lower negotiated drug prices is most impactful for enrollees with chronic conditions who take high-cost brand-name medications. A beneficiary taking Eliquis for atrial fibrillation or Jardiance for diabetes, for example, may hit the annual cap earlier in the year - meaning their out-of-pocket costs stop accumulating much sooner than they would have under prior rules.

For enrollees who take less expensive generic medications and rarely approach the old catastrophic threshold, the direct financial impact of the new cap may be modest. The change matters most to the subset of enrollees for whom annual drug costs were previously open-ended and unpredictable.

What the Cap Does Not Cover

There are important limits to what the 2,100-dollar cap applies to. It covers only drugs on a plan’s formulary. Medications that are not on a plan’s approved drug list do not count toward the cap - meaning out-of-pocket costs for those drugs could continue to accumulate separately. Monthly Part D premiums also do not count toward the cap, nor do drugs covered under Medicare Part B rather than Part D, such as certain physician-administered infusions.

AARP and Medicare planners have consistently noted that the annual open enrollment period - which runs each fall from October 15 through December 7 - remains the most important window for enrollees to compare plans based on their specific drug list, since formularies, deductibles, and cost-sharing structures can vary significantly from one plan to another. A plan with a lower monthly premium may not be the most cost-effective choice once a beneficiary’s specific medications are factored in.

A Structural Shift, Not a Complete Fix

The 2026 changes represent a meaningful structural improvement to Medicare’s drug benefit - particularly for the millions of Americans who take high-cost medications for serious chronic conditions. The cap provides a ceiling that simply did not exist before 2025. The negotiated prices reduce costs for specific high-use drugs at a scale that individual price comparison could not achieve.

For many Medicare enrollees, the experience at the pharmacy counter is already different this year than it was two years ago. For others, the changes are still working their way through plan formularies and coverage structures in ways that may take additional time to become visible.

References: 3 Big Medicare Prescription Drug Changes Coming in 2026 | Medicare Part D Out-of-Pocket Limit is $2,100 in 2026